New recommendations prioritise multiparametric MRI, safer transperineal biopsy, and earlier escalation for high-risk prostate-specific antigen relapse.

Patients who developed biochemical recurrence had a higher PSA at diagnosis, more advanced pT stages, a higher rate of pN1 stage disease, a higher rate of R1 or Rx resection, and a higher rate of ...

OBJECTIVES: To identify retrospectively through chart analysis the biochemical recurrence frequency of localized prostate cancer at diagnosis of patients submitted to surgery or radiotherapy; to ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

The prostate inflammation score of biopsy cores is associated with biochemical recurrence risk and might improve prediction of prostate cancer aggressiveness. The degree of inflammation in prostate ...

What happens if PSA levels start rising after surgery or radiation for prostate cancer? Up to a third of men treated for the disease will eventually confront this problem. If there's no accompanying ...

Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group PURPOSE: To assess the effect of nerve-sparing (NS) radical ...

XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI ...

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer. Postsurgical treatment with androgen deprivation therapy and Erleada ...

SAN ANTONIO -- More than 2 years after treatment, no patient with high-risk prostate cancer had a confirmed biochemical recurrence after receiving postoperative apalutamide (Erleada) and androgen ...

- If approved, XTANDI would become the first and only NHT treatment available for metastatic and high risk biochemical recurrent non-metastatic hormone sensitive prostate cancer patient populations in ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...